Steve E. Krognes, Director at Denali Therapeutics Inc. (DNLI), sold 92,500 shares at $20.50 ($1.9M) on 2024-04-01, disclosed to the SEC on 2024-04-02.
Scheduled sale ($1.9M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| DNLI | SELL | 2025-01-08 | $139K | — | Filing → |
| DNLI | SELL | 2025-01-03 | $608K | — | Filing → |
| DNLI | SELL | 2024-10-02 | $871K | — | Filing → |